Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Coya Therapeutics, Inc. (COYA)

Coya Therapeutics completes enrollment of 120-patient ALSTARS trial for COYA 302 in ALS

Neutral Impact 3 of 5 product/contract Written later

Coya Therapeutics announced that it has fully enrolled the planned 120 patients in its ongoing Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis (ALS). Topline data from the double-blind treatment phase are expected in early Q2 2027, a key clinical milestone for the company's lead program.

Key points

  • Full enrollment of the planned 120 patients in the ALSTARS Trial (NCT07161999) announced October 5, 2026
  • Additional participants already in active screening may enroll if deemed eligible
  • Topline data from the 24-week double-blind treatment phase anticipated in early Q2 2027
  • Primary endpoint is change in ALSFRS-R total score from baseline to Week 24 compared with placebo

The filing

CompanyCoya Therapeutics, Inc. (COYA)
Form8-K, current report
Filed with the SECOct 5, 2026, 8:30 AM ET
Accession number0001193125-26-413218

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.